Avoid common mistakes on your manuscript.
Sirs:
Bioprosthetic aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) is a promising technique to prevent ostial coronary occlusion during transcatheter aortic valve replacement (TAVR) [1]. BASILICA prohibits coronary artery obstruction by lacerating the leaflet in front of a threatened coronary artery ostium. The conception is that a sliced leaflet spreads after TAVR and creates a triangular space that allows blood flow towards the sinus and coronary artery, which otherwise would have been occluded. The probable advantage of BASILICA over coronary stent protection is that it directly addresses the valve leaflet itself whereas the latter one may be associated with external stent compression, deformation, and thrombosis with only challenging or impossible options of percutaneous reintervention. BASILICA may result in an easier coronary access after TAVR and does not leave additional material in the aortic root [2].
An 82-year-old female patient suffered from severe symptomatic bioprosthetic aortic valve stenosis (Sorin Mitroflow 21 mm) that was implanted 6 years ago. She had a patent left internal mammary graft to the left anterior descending artery, though the circumflex artery (Cx) was unprotected in a left dominant coronary artery system with only a hypoplastic right coronary artery. The HeartTeam decided for valve-in-valve TAVR due to increased surgical risk and porcelain aorta (STS 6.4%). However, she was at risk for coronary obstruction of the unprotected Cx due to the findings in the pre-interventional computed tomography. The combination of a low left main stem take-off (3.8 mm), a low sinotubular junction height (16.1 mm), a distance between the virtual transcatheter heart valve and the coronary ostium of 4.1 mm, and a distance between the virtual transcatheter heart valve and the sinotubular junction of 2.6 mm defined a type IIIB aortic root according to the VIVID classification [3] (Fig. 1a–d). This condition is associated with an increased risk of coronary obstruction following valve-in-valve TAVR, in particular in bioprostheses with externally mounted leaflets as in our case.
Computed tomography. Low LMS take-off, low STJ height (a) and narrow SOV (b). Relationship between a virtual THV and the LMS (c) and STJ (d). LMS left main stem, LCA left coronary artery, RCA right coronary artery, STJ sinotubular junction, THV transcatheter heart valve, VTC distance between the virtual THV and the coronary ostium, VT-STJ distance between the virtual THV and the sinotubular junction
A BASILICA procedure was performed under cerebral embolic protection (SENTINEL™, Boston Scientific Corporation, Marlborough, MA). Several traversal attempts with an electrified Astato XS 20 300-cm wire (ASAHI INTECC, Aichi, Japan) were unsuccessful due to severe calcification of the left coronary cusp. The combination of a suboptimal traversal angle with deviation of the wire into the left Sinus of Valsalva (SOV) and prolonged energy application caused laceration of the SOV (Fig. 2a–b). A hematoma developed around the left main stem (LMS) and the posterolateral left atrial wall without pericardial effusion, the patient remained hemodynamically stable (Fig. 2c, ESM Video 1). Further traversal attempts using a different guiding catheter with modified traversal angles were carried out being finally successful (Fig. 3a). ECG changes and concerns of external LMS compression led to angiography prior to laceration revealing embolized material in the Cx, which was treated by drug-eluting stent (DES) implantation (Fig. 3a, b, ESM Video 2). Another DES was positioned in the LMS/Cx followed by laceration of the left coronary cusp and implantation of an EvolutR 23 mm (Medtronic, Dublin, Ireland) (Fig. 3c). Finally, the pre-positioned stent was implanted in anticipation of possible hematoma progression leading to both unimpaired coronary flow and coverage of the laceration, thus stopping the bleeding into the hematoma (Fig. 3d–f, ESM Video 3). Sixteen hours later, the patient developed a localized pericardial tamponade requiring emergency pericardiocentesis (Fig. 4a–c). A prolonged intensive care stay due to pneumonia characterized the further clinical course; however, 34 days after the procedure, she was transferred to a rehab unit.
BASILICA procedure II. V-shape formation after successful traversal (a, solid arrow). Embolized material in the circumflex artery (a, dotted arrow) treated with a DES 3.5 × 16 mm (b). Prepositioning of another DES (4.0 × 24 mm), laceration of the left coronary cusp and implantation of an EvolutR 23 mm (c, d). Implantation of the stent with patent coronary flow and coverage of the laceration (e, f). DES drug-eluting stent
This case describes a potentially life-threatening complication of the BASILICA procedure that might be prevented by avoiding wire bending during the traversal attempt and prolonged energy application.
Change history
26 October 2021
A Correction to this paper has been published: https://doi.org/10.1007/s00392-021-01949-1
Reference
Khan JM, Greenbaum AB, Babaliaros VC, Rogers T, Eng MH, Paone G, Leshnower BG, Reisman M, Satler L, Waksman R, Chen MY, Stine AM, Tian X, Dvir D, Lederman RJ (2019) The BASILICA Trial: Prospective Multicenter Investigation of Intentional Leaflet Laceration to Prevent TAVR Coronary Obstruction. JACC CardiovascInterv 12:1240–1252
Komatsu I, Mackensen GB, Aldea GS, Reisman M, Dvir D: Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction. Part 2: how to perform BASILICA. EuroIntervention 2019;15:55–66
Tang GHL, Komatsu I, Tzemach L, Simonato M, Wolak A, Blanke P, Dvir D: Assessing the risk for coronary obstruction after transcatheter aortic valve implantation and the need to perform BASILICA: the VIVID classification. EuroIntervention 2020
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Norman Mangner reports personal fees from Edwards LifeScience, Medtronic, Biotronik, Novartis, Sanofi Genzyme, and AstraZeneca, outside the submitted work. Mohamed Abdel-Wahab has nothing to disclose. Krunoslav Sveric reports personal fees from Novartis and GlaxoSmithKline, outside the submitted work. Utz Kappert has nothing to disclose. Julia Fischer has nothing to disclose. Stephan Haussig has nothing to disclose. Axel Linke reports grants from Novartis, personal fees from Medtronic, Abbott, Edwards Lifesciences, Boston Scientific, Astra Zeneca, Novartis, Pfizer, Abiomed, Bayer, Boehringer, and other from Picardia, Transverse Medical, Claret Medical, outside the submitted work. Axel Linke reports grants from Novartis, personal fees from Medtronic, Abbott, Edwards Lifesciences, Boston Scientific, Astra Zeneca, Novartis, Pfizer, Abiomed, Bayer, Boehringer, and other from Picardia, Transverse Medical, Claret Medical, outside the submitted work.
Additional information
The original online version of this article was revised due to a retrospective Open Access order.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary file1 Video 1: Bending of the electrified wire causing laceration of the left Sinus of Valsalva confirmed by angiography and echocardiography. (AVI 1558 kb)
Supplementary file2 Video 2: Embolized material at the bifurcation of left circumflex and obtuse marginal treated by DES implantation. (MPG 4482 kb)
Supplementary file3 Video 3: Laceration of the left coronary cusp, TAVI implantation followed by DES implantation leading to patent coronary flow and coverage of the laceration. (AVI 6133 kb)
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mangner, N., Abdel-Wahab, M., Sveric, K. et al. An unintentional complication during an intentional procedure—Sinus of Valsalva laceration during BASILICA. Clin Res Cardiol 110, 754–757 (2021). https://doi.org/10.1007/s00392-020-01745-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-020-01745-3